Vanderbilt Vaccine Center Archives
Antibody mixture may help block Ebola virus infection
Feb. 6, 2020—A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus.
Carnahan named associate director of Vaccine Center
Feb. 6, 2020—Robert Carnahan, PhD, associate professor of Pediatrics and Radiology and Radiological Sciences, has been appointed associate director of the Vanderbilt Vaccine Center.
Antibody isolated at VUMC found to halt dengue virus
Jan. 23, 2020—Using part of an antibody isolated at Vanderbilt that “broadly neutralizes” the human dengue virus, biologists at the University of California San Diego and colleagues have disarmed the mosquito that transmits the disabling and potentially deadly tropical infection.
VUMC-led team isolates antibody that blocks bird flu
Dec. 12, 2019—VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans.
New tool may speed antibody, vaccine research
Dec. 12, 2019— by Allison Whitten The antibody discovery and vaccine development research fields may be on the verge of rapidly expanding with data that previously took decades to acquire, thanks to LIBRA-seq, a new tool developed by Vanderbilt University researchers and their colleagues. Currently, due to technological constraints, it can take up to a year to...
Partnership to help bring Zika virus therapy to clinic
Sep. 4, 2019—Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago.
Vanderbilt vaccine pioneer James Crowe honored with major science prize
Jul. 9, 2019—James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, will be honored today by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses.
New method tested to block chikungunya infection
Jun. 14, 2019—Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies.
VUMC joins international effort to speed vaccine development
Jun. 6, 2019—VUMC has joined an international effort to streamline and accelerate development of vaccines and other treatments against a growing worldwide surge of deadly and debilitating viral infections.
Flu’s “hidden target” may lead to universal vaccine: study
May. 16, 2019—Researchers at Vanderbilt University Medical Center and the Scripps Research Institute have discovered a “hidden target” on the surface of the hypervariable influenza A virus that could lead to better ways to prevent and treat the flu.
VUMC-led team ‘sprints’ to develop Zika virus treatment
Apr. 11, 2019—In January scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis were given an audacious goal to develop — in 90 days — a protective antibody-based treatment that potentially will stop the spread of the Zika virus.
VUMC joins effort to stop spread of two deadly viruses
Mar. 25, 2019—Researchers at Vanderbilt University Medical Center are participating in a national effort to develop vaccines and other treatments as countermeasures to prevent the spread of two emerging and deadly viruses — Nipah and Hendra.
